Abu Dhabi, UAE— Mubadala Health and G42, a UAE-based artificial intelligence and cloud computing technology company, on Thursday, announced they will merge their respective healthcare businesses to create a new integrated healthcare company.
The new company will consider opportunities for international expansion and new partnerships, Mubadala said. The new entity will also focus on collaboration with leading researchers and pharmaceutical and health-tech ecosystems.
Across the two organisations, healthcare assets today include Imperial College London Diabetes Centre; HealthPoint; National Reference Laboratory; HealthPlus; Danat Al Emarat; Moorfields Eye Hospital Abu Dhabi; Biogenix; the UAE’s Omics Centre of Excellence; and Insights Research Organisation & Solutions (IROS), the first UAE-based contract research organisation specialising in healthcare research.
Hasan Jasem Al Nowais has been appointed CEO of the new entity and will continue to lead Mubadala Health.
Peng Xiao, Group CEO of G42, stated, “We aim to build on the respective strengths of G42 Healthcare and Mubadala Health to unlock healthcare super-intelligence and facilitate global healthcare expansion. Our capabilities and experience in leveraging data and artificial intelligence will allow us to continue transforming the traditional healthcare ecosystem to deliver top-notch patient care, fuelled by the latest breakthrough research – all in world-class facilities.”
Waleed Al Mokarrab Al Muhairi, Chairman of Mubadala Health and Deputy CEO of Mubadala, said, “The future of healthcare lies in the incredible, fast-moving advances being made in technology. For over a decade, Mubadala has invested in the highest standard of patient care for the residents of the UAE across a number of specialities. We now seek to take patient care to the next level, into a new era of precision and personalised medicine.”